The laboratory diagnosis of lupus anticoagulant in patients on oral anticoagulation

被引:4
作者
Aboud, MR
Roddie, C
Ward, CM
Coyle, L
机构
[1] Royal N Shore Hosp, Pacific Lab Med Serv, Sydney, NSW, Australia
[2] Univ Sydney, No Blood Res Ctr, Sydney, NSW 2006, Australia
[3] Royal N Shore Hosp, Dept Haematol & Transfus Med, Sydney, NSW, Australia
来源
CLINICAL AND LABORATORY HAEMATOLOGY | 2006年 / 28卷 / 02期
关键词
lupus anticoagulant; oral anticoagulation; activated partial thromboplastin time; dilute Russel viper venom time; lupus ratio;
D O I
10.1111/j.1365-2257.2006.00753.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Laboratory-specific cut-off lupus ratios (LR), above which a plasma is judged positive for lupus anticoagulant (LA), were established for both activated partial thromboplastin time-based and dilute Russell viper venom time-based methods. The validity of using these cut-off values to determine the presence of LA in patients on oral anticoagulation (OAC) was assessed. A cohort of 40 patients (23 male and 17 female), aged 22-84 years (mean 52 years) were tested for LA at the time of a thrombotic event. Repeated testing was performed after the same patients were treated with OAC (international normalized ratio 2.0-3.5). For 36 patients (90%), LA status was unchanged pre- and on-OAC. Thirteen of the 40 patients (32.5%) were positive for LA both pre- and on-OAC. Of the 27 patients negative for LA pre-OAC, 23 remained negative on-OAC. The four discordant results were interesting in that LA positivity was demonstrated only after the patient was stable on-OAC. In our cohort of 40 patients, there was a trend for LRs to decrease on-OAC, but this did not reach statistical significance. The subset (4) went against this trend and became positive after the thrombotic event.
引用
收藏
页码:105 / 110
页数:6
相关论文
共 20 条
[1]   A comparison between two activated protein C resistance methods as routine diagnostic tests for factor V Leiden mutation [J].
Aboud, MR ;
Ma, DDF .
BRITISH JOURNAL OF HAEMATOLOGY, 1997, 97 (04) :798-803
[2]   Improved confirmation of weak lupus anticoagulants by employing sensitive and insensitive reagents to the lupus anticoagulant [J].
Ames, PRJ ;
Iannaccone, L ;
De Iasio, R ;
Brancaccio, V .
BLOOD COAGULATION & FIBRINOLYSIS, 2001, 12 (07) :563-567
[3]  
Arnout J, 1999, THROMB HAEMOSTASIS, V81, P929
[4]  
Arnout J, 2001, THROMB HAEMOSTASIS, V86, P83
[5]   STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT [J].
BLAND, JM ;
ALTMAN, DG .
LANCET, 1986, 1 (8476) :307-310
[6]   A rapid screen for lupus anticoagulant with good discrimination from oral anticoagulants, congenital factor deficiency and heparin, is provided by comparing a sensitive and an insensitive APTT reagent [J].
Brancaccio, V ;
Ames, PRJ ;
Glynn, J ;
Iannaccone, L ;
Mackie, IJ .
BLOOD COAGULATION & FIBRINOLYSIS, 1997, 8 (03) :155-160
[7]  
BRANDT JT, 1995, THROMB HAEMOSTASIS, V74, P1185
[8]  
EXNER T, 1995, THROMB HAEMOSTASIS, V74, P338
[9]   Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature [J].
Galli, M ;
Luciani, D ;
Bertolini, G ;
Barbui, T .
BLOOD, 2003, 101 (05) :1827-1832
[10]   Guidelines on the investigation and management of the antiphospholipid syndrome [J].
Greaves, M ;
Cohen, H ;
Machin, SJ ;
Mackie, I .
BRITISH JOURNAL OF HAEMATOLOGY, 2000, 109 (04) :704-715